Table 2 Treatment characteristics and dosimetric parameters
From: Treatment outcomes of passive scattering proton beam therapy for stage I non-small cell lung cancer
Characteristics | No | Range |
|---|---|---|
Total dose/fractions, (BED10)a | ||
60 CGE/4 fx (150) | 11 | |
50 CGE/4 fx (112.5) | 22 | |
70 CGE/10 fx (119) | 6 | |
60 CGE/10 fx (96) | 3 | |
PTV (cm3) | ||
Median | 34.55 | 9.6–84 |
Total lung, median (range) | ||
V5 (%) | 10.79 | 3.61–18.67 |
V10 (%) | 8.71 | 2.84–16.24 |
V15 (%) | 7.09 | 2.25–12.78 |
V20 (%) | 5.85 | 1.74–10.86 |
V30 (%) | 3.72 | 1.16–8.11 |
V40 (%) | 2.26 | 0.76–5.68 |
Mean dose (CGE) | 2.99 | 0.07–5.44 |
Heart, median (range) | ||
V5 (%) | 0 | 0–5.26 |
V10 (%) | 0 | 0–4.03 |
V15 (%) | 0 | 0–3.08 |
V20 (%) | 0 | 0–1.99 |
V30 (%) | 0 | 0–1.19 |
V40 (%) | 0 | 0–0.48 |
Mean dose (CGE) | 0.003 | 0.002–1.13 |
Max dose (CGE) | 0.2 | 0.002–63.74 |
Esophagus, median (range) | ||
Mean dose (CGE) | 0.003 | 0.002–1.36 |
Max dose (CGE) | 3.6 | 0 .08–17.55 |
Spinal cord, median (range) | ||
Max dose (CGE) | 0.006 | 0.002–14.1 |
Chest wall, median (range) | ||
Max dose (CGE) | 56.0 | 31.0–75.9 |